Latest Stroke Diagnosis News

EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.

EMVision Medical Devices reported a $3.97 million loss for H1 2026, up 11% year-on-year, driven by increased share-based payments and expanded clinical activities. The company secured a $3 million government grant to advance stroke diagnosis in regional Australia.

Micro-X has initiated installation of its first human pilot site for a portable Head CT scanner at Royal Melbourne Hospital, marking a pivotal step towards revolutionising stroke diagnosis with carbon nanotube technology.

EMVision Medical Devices reports strong clinical trial progress for its portable brain scanners, backed by solid cash reserves and milestone grant funding.

EMVision Medical Devices reports strong progress in its emu™ Brain Scanner clinical trials, expanding recruitment across seven leading stroke hospitals and introducing new software features to enhance scan quality.

Micro-X Limited has secured $6 million through a share placement to accelerate commercialisation of its innovative medical imaging technologies, with strategic partner Billion Prima increasing its stake to 8.5%. The capital raise supports key clinical trials and product development milestones.

Micro-X has raised $6.18 million through a placement that sees strategic partner Billion Prima increase its stake to 8.6%, funding key commercial and manufacturing scale-up initiatives in medical imaging.

EMVision Medical Devices has begun a pivotal aeromedical study with the Royal Flying Doctor Service to test its portable First Responder brain scanner in remote emergency settings. The trial aims to validate device usability and workflow integration ahead of commercial rollout.

Micro-X Ltd has secured its largest-ever $3.3 million Rover Plus order from Malaysia’s Ministry of Health and is progressing critical Head CT imaging trials, supported by a $4.4 million government grant.

EMVision Medical Devices has expanded its pivotal clinical trial sites, secured a $3 million government grant, and raised $14 million through placement and share purchase plan, positioning itself strongly for upcoming regulatory submissions and commercialisation.

EMVision Medical Devices has closed its $2 million Share Purchase Plan ahead of schedule due to strong investor demand, signaling robust market interest in its neurodiagnostic technology.

EMVision Medical Devices’ latest Share Purchase Plan has attracted applications exceeding its initial $1 million target, with limited oversubscription capacity remaining ahead of the October 23 closing date.